These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 15208817)

  • 1. New drug works with antiemetics to control acute and delayed nausea and vomiting.
    Clin J Oncol Nurs; 2004 Jun; 8(3):239. PubMed ID: 15208817
    [No Abstract]   [Full Text] [Related]  

  • 2. Aprepitant for chemotherapy-induced nausea and vomiting.
    Flemm LA
    Clin J Oncol Nurs; 2004 Jun; 8(3):303-6. PubMed ID: 15208824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiemetics: state of the art.
    Herrstedt J
    Eur J Cancer; 2009 Sep; 45 Suppl 1():439-41. PubMed ID: 19775663
    [No Abstract]   [Full Text] [Related]  

  • 4. The next generation of chemotherapy-induced nausea and vomiting prevention and control: a new 5-HT3 antagonist arrives.
    Rittenberg CN
    Clin J Oncol Nurs; 2004 Jun; 8(3):307-8, 310. PubMed ID: 15208825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omission of day 2 of antiemetic medications is a cost saving strategy for improving chemotherapy-induced nausea and vomiting control: results of a randomized phase III trial.
    Lajolo PP; de Camargo B; del Giglio A
    Am J Clin Oncol; 2009 Feb; 32(1):23-6. PubMed ID: 19194119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials.
    Warr DG; Grunberg SM; Gralla RJ; Hesketh PJ; Roila F; Wit Rd; Carides AD; Taylor A; Evans JK; Horgan KJ
    Eur J Cancer; 2005 Jun; 41(9):1278-85. PubMed ID: 15939263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Patient lack of knowledge about nausea in chemotherapy: becoming experts in their disease].
    Seeling S
    Pflege Z; 2005 Feb; 58(2):104-6. PubMed ID: 15754509
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparative activity of antiemetic drugs.
    Jordan K; Schmoll HJ; Aapro MS
    Crit Rev Oncol Hematol; 2007 Feb; 61(2):162-75. PubMed ID: 17208005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute and delayed nausea and emesis control in pediatric oncology patients.
    Holdsworth MT; Raisch DW; Frost J
    Cancer; 2006 Feb; 106(4):931-40. PubMed ID: 16404740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide.
    Shih V; Wan HS; Chan A
    Ann Pharmacother; 2009 Mar; 43(3):444-52. PubMed ID: 19193584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of a continuous infusion, patient controlled anti-emetic pump to facilitate outpatient administration of high-dose chemotherapy.
    Dix S; Cord M; Howard S; Coon J; Belt R; Geller R
    Bone Marrow Transplant; 1999 Sep; 24(5):561-6. PubMed ID: 10482943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
    Hargreaves R; Ferreira JC; Hughes D; Brands J; Hale J; Mattson B; Mills S
    Ann N Y Acad Sci; 2011 Mar; 1222():40-8. PubMed ID: 21434941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Granisetron oral phase III clinical trial--study on the inhibitory effect of granisetron for nausea/vomiting induced by chemotherapy for tumors in the hematopoietic organs].
    Hiraoka A; Masaoka T; Nagai K; Kakishita E; Oshiba S; Kageyama T; Okuda K; Tatsumi N; Uchino H; Matsuzawa Y
    Gan To Kagaku Ryoho; 1993 Sep; 20(12):1835-41. PubMed ID: 8397489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aprepitant (EMEND): the role of substance P in nausea and vomiting.
    Prommer E
    J Pain Palliat Care Pharmacother; 2005; 19(3):31-9. PubMed ID: 16219609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy.
    Arpornwirat W; Albert I; Hansen VL; Levin J; Bandekar RR; Grunberg SM
    Cancer; 2009 Dec; 115(24):5807-16. PubMed ID: 19834961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting.
    Voravud N; Sriuranpong V
    J Med Assoc Thai; 2005 Dec; 88(12):1790-6. PubMed ID: 16518975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant.
    Grote T; Hajdenberg J; Cartmell A; Ferguson S; Ginkel A; Charu V
    J Support Oncol; 2006 Sep; 4(8):403-8. PubMed ID: 17004515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapeutic potential of Granisetron (Kitryl) for the prevention of nausea and vomiting induced by cytostatic drugs].
    Gershanovich ML; Beresneva IA
    Vopr Onkol; 1998; 44(2):225-8. PubMed ID: 9615833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting.
    Massaro AM; Lenz KL
    Ann Pharmacother; 2005 Jan; 39(1):77-85. PubMed ID: 15562136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of tropisetron and granisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy.
    Aksoylar S; Akman SA; Ozgenç F; Kansoy S
    Pediatr Hematol Oncol; 2001 Sep; 18(6):397-406. PubMed ID: 11554235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.